68Ga-PSMA-PET/CT in patients with biochemical prostate cancer recurrence and negative 18F-Choline-PET/CT

Clinical Nuclear Medicine

Volumn 41, Issue 7, 2016, Pages 515-521

  Bluemel, Christina ^a   Krebs, Markus ^a   Polat, Bülent ^a   Linke, Fränze ^b   Eiber, Matthias ^c   Samnick, Samuel ^a   Lapa, Constantin ^a   Lassmann, Michael ^a   Riedmiller, Hubertus ^a   Czernin, Johannes ^d   Rubello, Domenico ^e   Bley, Thorsten ^a   Kropf, Saskia ^f   Wester, Hans Juergen ^c   Buck, Andreas K ^a   Herrmann, Ken ^a,d  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b Klinikum Ansbach   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Rovigo Hospital   (Italy)

^f SCINTOMICS GMBH   (Germany)

Author keywords

Choline PET CT; Prostate cancer; PSMA PET CT; Recurrence; Restaging

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CHOLINE F 18; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN GA 68; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; CHOLINE; FLUOROMETHYLCHOLINE; GALLIUM; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN;

ADULT; AGED; ARTICLE; BIOCHEMICAL RECURRENCE; BONE METASTASIS; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORRELATIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; IMAGE ANALYSIS; IMAGING SOFTWARE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PATIENT PARTICIPATION; PET-CT SCANNER; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; REFUSAL TO PARTICIPATE; RETROSPECTIVE STUDY; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; ANALOGS AND DERIVATIVES; DIAGNOSTIC IMAGING; METABOLISM; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROCEDURES; PROSTATE TUMOR; TUMOR RECURRENCE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIGENS, SURFACE; CHOLINE; GALLIUM RADIOISOTOPES; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PROSTATIC NEOPLASMS;

EID: 84961230987     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0000000000001197     Document Type: Article

References (39)

1. Uchio EM, Aslan M, Wells CK, et al. Impact of biochemical recurrence in prostate cancer among US veterans. Arch Intern Med. 2010;170:1390-1395.
2. Mottet N, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011;59:572-583.
3. Pfister D, Bolla M, Briganti A, et al. Early salvage radiotherapy following radical prostatectomy. Eur Urol. 2014;65:1034-1043.
4. Trock BJ, Han M, Freedland SJ, et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA. 2008;299:2760-2769.
5. Schiavina R, Ceci F, Borghesi M, et al. The dilemma of localizing disease relapse after radical treatment for prostate cancer: which is the value of the actual imaging techniques? Curr Radiopharm. 2013;6:92-95.
6. Ceci F, Herrmann K, Castellucci P, et al. Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial. Eur J Nucl Med Mol Imaging. 2014;41: 2222-2231.
7. Krause BJ, Souvatzoglou M, Tuncel M, et al. The detection rate of [11C] choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35:18-23.
8. Castellucci P, Picchio M. 11C-choline PET/CTand PSA kinetics. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 1: S36-40.
9. Castellucci P, Ceci F, Graziani T, et al. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy? J Nucl Med. 2014;55:1424-1429.
10. Beer AJ, Eiber M, Souvatzoglou M, et al. Radionuclide and hybrid imaging of recurrent prostate cancer. Lancet Oncol. 2011;12:181-191.
11. Silver DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81-85.
12. Murphy GP, Elgamal AA, Su SL, et al. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer. 1998;83:2259-2269.
13. Bostwick DG, Pacelli A, Blute M, et al. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 1998;82:2256-2261.
14. Ross JS, Sheehan CE, Fisher HA, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res. 2003;9:6357-6362.
15. Eder M, Schafer M, Bauder-Wust U, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23:688-697.
16. Weineisen M, Simecek J, Schottelius M, et al. Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. EJNMMI Res. 2014;4:63.
17. Ceci F, Uprimny C, Nilica B, et al. Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging. vol. 42. 2015:1284-1294.
18. Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197-209.
19. Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of hybrid 68Ga- PSMA Ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668-674.
20. Weineisen M, Schottelius M, Simecek J, et al. Development and first in human evaluation of PSMA I&T-A ligand for diagnostic imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2014;55:1083.
21. Israel I, Richter D, Stritzker J, et al. PET imaging with [68Ga]NOTA-RGD for prostate cancer: a comparative study with [18F]fluorodeoxyglucose and [18F]fluoroethylcholine. Curr Cancer Drug Targets. 2014;14: 371-379.
22. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281: 1591-1597.
23. Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:11-20.
24. Afshar-Oromieh A, Malcher A, Eder M, et al. PET imaging with a [68Ga] gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486-495.
25. Fanti S, Minozzi S, Castellucci P, et al. PET/CTwith 11C-Choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data. vol. 43. 2016:55-69.
26. Rinnab L, Mottaghy FM, Blumstein NM, et al. Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int. 2007;100:786-793.
27. Rinnab L, Simon J, Hautmann RE, et al. [(11)C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy. World J Urol. 2009;27:619-625.
28. Ceci F, Castellucci P, Graziani T, et al. 11C-choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT. Eur J Nucl Med Mol Imaging. 2014;41:878-886.
29. Brogsitter C, Zöphel K, Kotzerke J. 6-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients. Eur J Nucl Med Mol Imaging 2013;40 Suppl 1:S18-7.
30. Buchegger F, Garibotto V, Zilli T, et al. First imaging results of an intraindividual comparison of (11)C-acetate and (18)F-fluorocholine PET/ CT in patients with prostate cancer at early biochemical first or second relapse after prostatectomy or radiotherapy. Eur J Nucl Med Mol Imaging. 2014;41:68-78.
31. Graute V, Jansen N, Ubleis C, et al. Relationship between PSA kinetics and [18 F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy. Eur J Nucl Med Mol Imaging. 2012;39:271-282.
32. Castellucci P, Fuccio C, Rubello D, et al. Is there a role for 11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase
33. Mamede M, Ceci F, Castellucci P, et al. The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level <0.5 ng/mL. Clin Nucl Med. 2013;38: e342-345.
34. Morigi JJ, Stricker P, Van Leeuwen P, et al. Prospective comparison of 18 F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med. 2015;56:1185-90.
35. Velikyan I. Prospective of 68Ga-radiopharmaceutical development. Theranostics. 2013;4:47-80.
36. Herrmann K, Lapa C, Wester HJ, et al. Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe 68Ga-pentixafor. J Nucl Med. 2015;56:410-416.
37. Szabo Z, Mena E, Rowe SP, et al. Mol Imaging Biol. 2015:17-74.
38. Malik N, Baur B, Winter G, et al. Radiofluorination of PSMA-HBED via AlF chelation and biological evaluations in vitro. Mol Imaging Biol. 2015:17-85.
39. Dietlein M, Kobe C, Kuhnert G, et al. Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer. Mol Imaging Biol. 2015;17: 575-84.